STUDY OBJECTIVES: To assess the effectiveness of CPAP treatment in improving 90-minute driving simulator performance in severe OSA patients compared to age/gender matched controls. DESIGN: Driving simulator performance was assessed at baseline and 3 months later, with OSA patients treated with CPAP during the interval. SETTING: University Teaching Hospital. PARTICIPANTS: Patients with severe OSA (n = 11) and control subjects without OSA (n = 9). INTERVENTIONS: CPAP MEASUREMENTS AND RESULTS: Simulator driving parameters of steering deviation, braking reaction time and crashes were measured at baseline and ∼3 months follow-up. At baseline, OSA subjects demonstrated significantly greater steering deviation compared to controls (mean [95% CI], OSA group, 49.9 cm [43.7 to 56.0 cm] vs control group, 34.9 cm [28.1 to 41.7 cm], p = 0.003). Following ∼3 months of CPAP treatment (mean ± SD 6.0 ± 1.4 h/night), steering deviation in OSA subjects improved by an average of 3.1 cm (CI, 1.4 to 4.9), p < 0.001, while no significant steering changes were observed in the control group. Despite the improvement, steering deviation in the OSA group remained significantly higher than in controls (OSA group, 46.7 cm [CI, 40.6 to 52.8 cm] vs control group, 36.1 cm [CI, 29.3 to 42.9 cm], p = 0.025). CONCLUSIONS: While driving simulator performance improved after ∼3 months of CPAP treatment with high adherence in patients with severe OSA, performance remained impaired compared to control subjects. These results add to the growing body of evidence that some neurobehavioral deficits in patients with severe OSA are not fully reversed by treatment. Further studies are needed to assess causes of residual driving simulator impairment and to determine whether this is associated with persistent elevated real-life accident risk. TRIAL REGISTRATION: Data presented in this manuscript was collected as part of a clinical trial "Experimental Investigations of Driving Impairment in Obstructive Sleep Apnoea" ACTRN12610000009011, http://www.anzctr.org.au/trial_view.aspx?ID=334979
STUDY OBJECTIVES: To assess the effectiveness of CPAP treatment in improving 90-minute driving simulator performance in severe OSA patients compared to age/gender matched controls. DESIGN: Driving simulator performance was assessed at baseline and 3 months later, with OSA patients treated with CPAP during the interval. SETTING: University Teaching Hospital. PARTICIPANTS: Patients with severe OSA (n = 11) and control subjects without OSA (n = 9). INTERVENTIONS:CPAP MEASUREMENTS AND RESULTS: Simulator driving parameters of steering deviation, braking reaction time and crashes were measured at baseline and ∼3 months follow-up. At baseline, OSA subjects demonstrated significantly greater steering deviation compared to controls (mean [95% CI], OSA group, 49.9 cm [43.7 to 56.0 cm] vs control group, 34.9 cm [28.1 to 41.7 cm], p = 0.003). Following ∼3 months of CPAP treatment (mean ± SD 6.0 ± 1.4 h/night), steering deviation in OSA subjects improved by an average of 3.1 cm (CI, 1.4 to 4.9), p < 0.001, while no significant steering changes were observed in the control group. Despite the improvement, steering deviation in the OSA group remained significantly higher than in controls (OSA group, 46.7 cm [CI, 40.6 to 52.8 cm] vs control group, 36.1 cm [CI, 29.3 to 42.9 cm], p = 0.025). CONCLUSIONS: While driving simulator performance improved after ∼3 months of CPAP treatment with high adherence in patients with severe OSA, performance remained impaired compared to control subjects. These results add to the growing body of evidence that some neurobehavioral deficits in patients with severe OSA are not fully reversed by treatment. Further studies are needed to assess causes of residual driving simulator impairment and to determine whether this is associated with persistent elevated real-life accident risk. TRIAL REGISTRATION: Data presented in this manuscript was collected as part of a clinical trial "Experimental Investigations of Driving Impairment in Obstructive Sleep Apnoea" ACTRN12610000009011, http://www.anzctr.org.au/trial_view.aspx?ID=334979
Authors: F Barbé; L R Mayoralas; J Duran; J F Masa; A Maimó; J M Montserrat; C Monasterio; M Bosch; A Ladaria; M Rubio; R Rubio; M Medinas; L Hernandez; S Vidal; N J Douglas; A G Agustí Journal: Ann Intern Med Date: 2001-06-05 Impact factor: 25.391
Authors: Jasmohan S Bajaj; Leroy R Thacker; David Leszczyszyn; Samuel A Taylor; Douglas M Heuman; Shekar Raman; Richard K Sterling; Muhammad S Siddiqui; R Todd Stravitz; Arun J Sanyal; Puneet Puri; Velimir Luketic; Scott Matherly; Michael Fuchs; Melanie B White; Nicole A Noble; Ariel B Unser; James B Wade Journal: Clin Gastroenterol Hepatol Date: 2014-08-23 Impact factor: 11.382
Authors: Scott G Williams; Jacob Collen; Emerson Wickwire; Christopher J Lettieri; Vincent Mysliwiec Journal: Curr Psychiatry Rep Date: 2014-08 Impact factor: 5.285
Authors: Kevin D Johnson; Sanjay R Patel; Dorothee M Baur; Edward Edens; Patrick Sherry; Atul Malhotra; Stefanos N Kales Journal: J Occup Environ Med Date: 2014-05 Impact factor: 2.162
Authors: William C Chen; Eric Y Chen; Rahiwa Z Gebre; Michelle R Johnson; Ningcheng Li; Petr Vitkovskiy; Hal Blumenfeld Journal: Epilepsy Behav Date: 2014-01 Impact factor: 2.937
Authors: Kingman P Strohl; Daniel B Brown; Nancy Collop; Charles George; Ronald Grunstein; Fang Han; Lawrence Kline; Atul Malhotra; Alan Pack; Barbara Phillips; Daniel Rodenstein; Richard Schwab; Terri Weaver; Kevin Wilson Journal: Am J Respir Crit Care Med Date: 2013-06-01 Impact factor: 21.405
Authors: Marco Túlio de Mello; Fernanda Veruska Narciso; Sergio Tufik; Teresa Paiva; David Warren Spence; Ahmed S Bahammam; Joris C Verster; Seithikurippu R Pandi-Perumal Journal: Int J Prev Med Date: 2013-03